Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Innovent Biologics, Inc. ("I...
In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weig...
HDT Bio, a clinical-stage biotechnology company based in Seattle, Washington,announced that it received the Medical CBRN Defense Consortium (MCDC) Innova...
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced p...
European Medicines Agency (EMA) has adopted a positive opinion recommending approval of nerandomilast for the treatment of idiopathic pulmonary fibrosis ...
Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, announced that the first patient has been dosed...
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD ...
IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. Maximum dose reached with no dose-limiting toxicities obser...
SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in i...
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced so...
LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company develo...
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B-Targeting Antibody Demonstrates Potential to Become a Bes...
Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tok...
As clinical development grows more complex and globally interconnected, biotech companies are under increasing pressure to build CRO partnerships that deli...
© 2026 Biopharma Boardroom. All Rights Reserved.
